Get started
Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 ShAlnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 ShAlnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh

Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh

No trades
OverviewFinancialsNewsCommunityTechnicalsSeasonalsBonds

Chart


Full chart

Key stats


Market capitalization
‪231.68 B‬ BRL
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
133,000.000
Basic EPS (TTM)
0.001 BRL
Net income (FY)
‪1.75 B‬ BRL
Revenue (FY)
‪20.75 B‬ BRL
Shares float
—
Beta (1Y)
−0.26

About Alnylam Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Yvonne L. Greenstreet
Website
alnylam.com
Headquarters
Cambridge
Founded
2002
IPO date
May 28, 2004
Identifiers
2
ISIN BRA1LNBDR003
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as A1LN34.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


US2043QAC1
Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028
Yield to maturity
—
Maturity date
Sep 15, 2028
ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027
Yield to maturity
—
Maturity date
Sep 15, 2027

See all A1LN34 bonds